HeartFlow turns a standard heart CT scan into a 3D digital model using AI to show blood flow and blockages, helping doctors diagnose coronary artery disease without invasive tests.
Revenue comes from selling its HeartFlow Platform to hospitals and clinics, with gross margins around 80% but net losses due to heavy R&D and sales costs.
Its AI-driven, FDA-cleared technology is deeply integrated into clinical workflows, making it hard for competitors like Siemens Healthineers and GE HealthCare to displace quickly, though reimbursement changes and competition could erode its edge.
Hold (sector percentile 35) — value C-, growth C+, profitability C+, momentum A-, revisions C+. Updated daily, sector-relative, identical for every user.
Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
